[
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00054",
      "source": "DB00001",
      "target": "DB00054",
      "description": "Lepirudin may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00009",
      "source": "DB00001",
      "target": "DB00009",
      "description": "Alteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00029",
      "source": "DB00001",
      "target": "DB00029",
      "description": "Anistreplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00102",
      "source": "DB00001",
      "target": "DB00102",
      "description": "Lepirudin may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00006",
      "source": "DB00001",
      "target": "DB00006",
      "description": "Lepirudin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00091",
      "source": "DB00001",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00055",
      "source": "DB00001",
      "target": "DB00055",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Lepirudin.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00063",
      "source": "DB00001",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Lepirudin.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00005",
      "source": "DB00001",
      "target": "DB00005",
      "description": "Etanercept may increase the anticoagulant activities of Lepirudin.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00078",
      "source": "DB00001",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00015",
      "source": "DB00001",
      "target": "DB00015",
      "description": "Reteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00086",
      "source": "DB00001",
      "target": "DB00086",
      "description": "Streptokinase may increase the anticoagulant activities of Lepirudin.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00031",
      "source": "DB00001",
      "target": "DB00031",
      "description": "Tenecteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00081",
      "source": "DB00001",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00001-DB00013",
      "source": "DB00001",
      "target": "DB00013",
      "description": "Urokinase may increase the anticoagulant activities of Lepirudin.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00002-DB00072",
      "source": "DB00002",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cetuximab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00004-DB00072",
      "source": "DB00004",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Denileukin diftitox.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00054",
      "source": "DB00005",
      "target": "DB00054",
      "description": "Etanercept may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00051",
      "source": "DB00005",
      "target": "DB00051",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Etanercept.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00026",
      "source": "DB00005",
      "target": "DB00026",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00102",
      "source": "DB00005",
      "target": "DB00102",
      "description": "Etanercept may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00006",
      "source": "DB00005",
      "target": "DB00006",
      "description": "Etanercept may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00091",
      "source": "DB00005",
      "target": "DB00091",
      "description": "Etanercept may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00035",
      "source": "DB00005",
      "target": "DB00035",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.",
      "name": "Desmopressin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00065",
      "source": "DB00005",
      "target": "DB00065",
      "description": "Etanercept may increase the immunosuppressive activities of Infliximab.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00001",
      "source": "DB00005",
      "target": "DB00001",
      "description": "Etanercept may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00073",
      "source": "DB00005",
      "target": "DB00073",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.",
      "name": "Rituximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00005-DB00072",
      "source": "DB00005",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Etanercept.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00054",
      "source": "DB00006",
      "target": "DB00054",
      "description": "Bivalirudin may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00009",
      "source": "DB00006",
      "target": "DB00009",
      "description": "Alteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00029",
      "source": "DB00006",
      "target": "DB00029",
      "description": "Anistreplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00102",
      "source": "DB00006",
      "target": "DB00102",
      "description": "Bivalirudin may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00091",
      "source": "DB00006",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00055",
      "source": "DB00006",
      "target": "DB00055",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Bivalirudin.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00063",
      "source": "DB00006",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00005",
      "source": "DB00006",
      "target": "DB00005",
      "description": "Etanercept may increase the anticoagulant activities of Bivalirudin.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00078",
      "source": "DB00006",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00001",
      "source": "DB00006",
      "target": "DB00001",
      "description": "Lepirudin may increase the anticoagulant activities of Bivalirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00015",
      "source": "DB00006",
      "target": "DB00015",
      "description": "Reteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00086",
      "source": "DB00006",
      "target": "DB00086",
      "description": "Streptokinase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00031",
      "source": "DB00006",
      "target": "DB00031",
      "description": "Tenecteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00081",
      "source": "DB00006",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00006-DB00013",
      "source": "DB00006",
      "target": "DB00013",
      "description": "Urokinase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00008-DB00041",
      "source": "DB00008",
      "target": "DB00041",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.",
      "name": "Aldesleukin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00014",
      "source": "DB00007",
      "target": "DB00014",
      "description": "Leuprolide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00047",
      "source": "DB00007",
      "target": "DB00047",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00046",
      "source": "DB00007",
      "target": "DB00046",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00071",
      "source": "DB00007",
      "target": "DB00071",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Leuprolide.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00104",
      "source": "DB00007",
      "target": "DB00104",
      "description": "Octreotide may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00007-DB00072",
      "source": "DB00007",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Leuprolide.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00054",
      "source": "DB00009",
      "target": "DB00054",
      "description": "Alteplase may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00102",
      "source": "DB00009",
      "target": "DB00102",
      "description": "Alteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00006",
      "source": "DB00009",
      "target": "DB00006",
      "description": "Alteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00063",
      "source": "DB00009",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Alteplase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00009-DB00001",
      "source": "DB00009",
      "target": "DB00001",
      "description": "Alteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00047",
      "source": "DB00014",
      "target": "DB00047",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00046",
      "source": "DB00014",
      "target": "DB00046",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00071",
      "source": "DB00014",
      "target": "DB00071",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Goserelin.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00007",
      "source": "DB00014",
      "target": "DB00007",
      "description": "Leuprolide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00104",
      "source": "DB00014",
      "target": "DB00104",
      "description": "Octreotide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00014-DB00072",
      "source": "DB00014",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Goserelin.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00054",
      "source": "DB00013",
      "target": "DB00054",
      "description": "Urokinase may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00102",
      "source": "DB00013",
      "target": "DB00102",
      "description": "Urokinase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00006",
      "source": "DB00013",
      "target": "DB00006",
      "description": "Urokinase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00063",
      "source": "DB00013",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Urokinase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00013-DB00001",
      "source": "DB00013",
      "target": "DB00001",
      "description": "Urokinase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00054",
      "source": "DB00015",
      "target": "DB00054",
      "description": "Reteplase may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00102",
      "source": "DB00015",
      "target": "DB00102",
      "description": "Reteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00006",
      "source": "DB00015",
      "target": "DB00006",
      "description": "Reteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00063",
      "source": "DB00015",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Reteplase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00015-DB00001",
      "source": "DB00015",
      "target": "DB00001",
      "description": "Reteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00018-DB00041",
      "source": "DB00018",
      "target": "DB00041",
      "description": "The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.",
      "name": "Aldesleukin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00023-DB00072",
      "source": "DB00023",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Asparaginase.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00022-DB00041",
      "source": "DB00022",
      "target": "DB00041",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.",
      "name": "Aldesleukin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00051",
      "source": "DB00026",
      "target": "DB00051",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00005",
      "source": "DB00026",
      "target": "DB00005",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00065",
      "source": "DB00026",
      "target": "DB00065",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00073",
      "source": "DB00026",
      "target": "DB00073",
      "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.",
      "name": "Rituximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00026-DB00072",
      "source": "DB00026",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Anakinra.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00027-DB00091",
      "source": "DB00027",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Gramicidin D.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00054",
      "source": "DB00029",
      "target": "DB00054",
      "description": "Anistreplase may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00102",
      "source": "DB00029",
      "target": "DB00102",
      "description": "Anistreplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00006",
      "source": "DB00029",
      "target": "DB00006",
      "description": "Anistreplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00063",
      "source": "DB00029",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Anistreplase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00029-DB00001",
      "source": "DB00029",
      "target": "DB00001",
      "description": "Anistreplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00047",
      "source": "DB00030",
      "target": "DB00047",
      "description": "Insulin Human may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00046",
      "source": "DB00030",
      "target": "DB00046",
      "description": "Insulin Human may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00071",
      "source": "DB00030",
      "target": "DB00071",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00104",
      "source": "DB00030",
      "target": "DB00104",
      "description": "Insulin Human may increase the hypoglycemic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00030-DB00082",
      "source": "DB00030",
      "target": "DB00082",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Human.",
      "name": "Pegvisomant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00054",
      "source": "DB00031",
      "target": "DB00054",
      "description": "Tenecteplase may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00102",
      "source": "DB00031",
      "target": "DB00102",
      "description": "Tenecteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00006",
      "source": "DB00031",
      "target": "DB00006",
      "description": "Tenecteplase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00063",
      "source": "DB00031",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Tenecteplase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00031-DB00001",
      "source": "DB00031",
      "target": "DB00001",
      "description": "Tenecteplase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00034-DB00041",
      "source": "DB00034",
      "target": "DB00041",
      "description": "The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.",
      "name": "Aldesleukin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00038-DB00072",
      "source": "DB00038",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Oprelvekin.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00035-DB00005",
      "source": "DB00035",
      "target": "DB00005",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00034",
      "source": "DB00041",
      "target": "DB00034",
      "description": "The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.",
      "name": "Interferon Alfa-2a, Recombinant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00018",
      "source": "DB00041",
      "target": "DB00018",
      "description": "The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.",
      "name": "Interferon alfa-n3"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00069",
      "source": "DB00041",
      "target": "DB00069",
      "description": "The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.",
      "name": "Interferon alfacon-1"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00008",
      "source": "DB00041",
      "target": "DB00008",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.",
      "name": "Peginterferon alfa-2a"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00022",
      "source": "DB00041",
      "target": "DB00022",
      "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.",
      "name": "Peginterferon alfa-2b"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00086",
      "source": "DB00041",
      "target": "DB00086",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00041-DB00072",
      "source": "DB00041",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Aldesleukin.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00042-DB00083",
      "source": "DB00042",
      "target": "DB00083",
      "description": "Botulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.",
      "name": "Botulinum Toxin Type A"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00014",
      "source": "DB00046",
      "target": "DB00014",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00047",
      "source": "DB00046",
      "target": "DB00047",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00030",
      "source": "DB00046",
      "target": "DB00030",
      "description": "Insulin Human may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00071",
      "source": "DB00046",
      "target": "DB00071",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00007",
      "source": "DB00046",
      "target": "DB00007",
      "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00104",
      "source": "DB00046",
      "target": "DB00104",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00046-DB00082",
      "source": "DB00046",
      "target": "DB00082",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Pegvisomant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00014",
      "source": "DB00047",
      "target": "DB00014",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00030",
      "source": "DB00047",
      "target": "DB00030",
      "description": "Insulin Human may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00046",
      "source": "DB00047",
      "target": "DB00046",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00071",
      "source": "DB00047",
      "target": "DB00071",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00007",
      "source": "DB00047",
      "target": "DB00007",
      "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00104",
      "source": "DB00047",
      "target": "DB00104",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00047-DB00082",
      "source": "DB00047",
      "target": "DB00082",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Pegvisomant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00026",
      "source": "DB00051",
      "target": "DB00026",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00091",
      "source": "DB00051",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00005",
      "source": "DB00051",
      "target": "DB00005",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Etanercept.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00065",
      "source": "DB00051",
      "target": "DB00065",
      "description": "Adalimumab may increase the immunosuppressive activities of Infliximab.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00073",
      "source": "DB00051",
      "target": "DB00073",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Rituximab.",
      "name": "Rituximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00051-DB00072",
      "source": "DB00051",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Adalimumab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00056-DB00072",
      "source": "DB00056",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00054",
      "source": "DB00055",
      "target": "DB00054",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00102",
      "source": "DB00055",
      "target": "DB00102",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00006",
      "source": "DB00055",
      "target": "DB00006",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00063",
      "source": "DB00055",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00055-DB00001",
      "source": "DB00055",
      "target": "DB00001",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00058-DB00091",
      "source": "DB00058",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00009",
      "source": "DB00054",
      "target": "DB00009",
      "description": "Alteplase may increase the anticoagulant activities of Abciximab.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00029",
      "source": "DB00054",
      "target": "DB00029",
      "description": "Anistreplase may increase the anticoagulant activities of Abciximab.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00102",
      "source": "DB00054",
      "target": "DB00102",
      "description": "Abciximab may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00006",
      "source": "DB00054",
      "target": "DB00006",
      "description": "Bivalirudin may increase the anticoagulant activities of Abciximab.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00055",
      "source": "DB00054",
      "target": "DB00055",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Abciximab.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00063",
      "source": "DB00054",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Abciximab.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00005",
      "source": "DB00054",
      "target": "DB00005",
      "description": "Etanercept may increase the anticoagulant activities of Abciximab.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00078",
      "source": "DB00054",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00001",
      "source": "DB00054",
      "target": "DB00001",
      "description": "Lepirudin may increase the anticoagulant activities of Abciximab.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00015",
      "source": "DB00054",
      "target": "DB00015",
      "description": "Reteplase may increase the anticoagulant activities of Abciximab.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00086",
      "source": "DB00054",
      "target": "DB00086",
      "description": "Streptokinase may increase the anticoagulant activities of Abciximab.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00031",
      "source": "DB00054",
      "target": "DB00031",
      "description": "Tenecteplase may increase the anticoagulant activities of Abciximab.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00081",
      "source": "DB00054",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00054-DB00013",
      "source": "DB00054",
      "target": "DB00013",
      "description": "Urokinase may increase the anticoagulant activities of Abciximab.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00059-DB00072",
      "source": "DB00059",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pegaspargase.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00060-DB00072",
      "source": "DB00060",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Interferon beta-1a.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00054",
      "source": "DB00063",
      "target": "DB00054",
      "description": "Eptifibatide may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00009",
      "source": "DB00063",
      "target": "DB00009",
      "description": "Eptifibatide may increase the anticoagulant activities of Alteplase.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00029",
      "source": "DB00063",
      "target": "DB00029",
      "description": "Eptifibatide may increase the anticoagulant activities of Anistreplase.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00102",
      "source": "DB00063",
      "target": "DB00102",
      "description": "Eptifibatide may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00006",
      "source": "DB00063",
      "target": "DB00006",
      "description": "Eptifibatide may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00055",
      "source": "DB00063",
      "target": "DB00055",
      "description": "Eptifibatide may increase the anticoagulant activities of Drotrecogin alfa.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00078",
      "source": "DB00063",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00001",
      "source": "DB00063",
      "target": "DB00001",
      "description": "Eptifibatide may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00015",
      "source": "DB00063",
      "target": "DB00015",
      "description": "Eptifibatide may increase the anticoagulant activities of Reteplase.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00086",
      "source": "DB00063",
      "target": "DB00086",
      "description": "Eptifibatide may increase the anticoagulant activities of Streptokinase.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00031",
      "source": "DB00063",
      "target": "DB00031",
      "description": "Eptifibatide may increase the anticoagulant activities of Tenecteplase.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00081",
      "source": "DB00063",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00063-DB00013",
      "source": "DB00063",
      "target": "DB00013",
      "description": "Eptifibatide may increase the anticoagulant activities of Urokinase.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00051",
      "source": "DB00065",
      "target": "DB00051",
      "description": "Adalimumab may increase the immunosuppressive activities of Infliximab.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00026",
      "source": "DB00065",
      "target": "DB00026",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00005",
      "source": "DB00065",
      "target": "DB00005",
      "description": "Etanercept may increase the immunosuppressive activities of Infliximab.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00073",
      "source": "DB00065",
      "target": "DB00073",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.",
      "name": "Rituximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00065-DB00072",
      "source": "DB00065",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Infliximab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00068-DB00072",
      "source": "DB00068",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Interferon beta-1b.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00069-DB00041",
      "source": "DB00069",
      "target": "DB00041",
      "description": "The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.",
      "name": "Aldesleukin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00014",
      "source": "DB00071",
      "target": "DB00014",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00047",
      "source": "DB00071",
      "target": "DB00047",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00030",
      "source": "DB00071",
      "target": "DB00030",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00046",
      "source": "DB00071",
      "target": "DB00046",
      "description": "Insulin Pork may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00007",
      "source": "DB00071",
      "target": "DB00007",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00071-DB00104",
      "source": "DB00071",
      "target": "DB00104",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00051",
      "source": "DB00073",
      "target": "DB00051",
      "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Rituximab.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00026",
      "source": "DB00073",
      "target": "DB00026",
      "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00005",
      "source": "DB00073",
      "target": "DB00005",
      "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00065",
      "source": "DB00073",
      "target": "DB00065",
      "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00073-DB00072",
      "source": "DB00073",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Rituximab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00074-DB00072",
      "source": "DB00074",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Basiliximab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00075-DB00072",
      "source": "DB00075",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Muromonab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00051",
      "source": "DB00072",
      "target": "DB00051",
      "description": "Trastuzumab may increase the neutropenic activities of Adalimumab.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00041",
      "source": "DB00072",
      "target": "DB00041",
      "description": "Trastuzumab may increase the cardiotoxic activities of Aldesleukin.",
      "name": "Aldesleukin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00092",
      "source": "DB00072",
      "target": "DB00092",
      "description": "Trastuzumab may increase the neutropenic activities of Alefacept.",
      "name": "Alefacept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00087",
      "source": "DB00072",
      "target": "DB00087",
      "description": "Trastuzumab may increase the cardiotoxic activities of Alemtuzumab.",
      "name": "Alemtuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00026",
      "source": "DB00072",
      "target": "DB00026",
      "description": "Trastuzumab may increase the neutropenic activities of Anakinra.",
      "name": "Anakinra"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00098",
      "source": "DB00072",
      "target": "DB00098",
      "description": "Trastuzumab may increase the neutropenic activities of Anti-thymocyte Globulin (Rabbit).",
      "name": "Anti-thymocyte Globulin (Rabbit)"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00023",
      "source": "DB00072",
      "target": "DB00023",
      "description": "Trastuzumab may increase the cardiotoxic activities of Asparaginase.",
      "name": "Asparaginase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00074",
      "source": "DB00072",
      "target": "DB00074",
      "description": "Trastuzumab may increase the neutropenic activities of Basiliximab.",
      "name": "Basiliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00002",
      "source": "DB00072",
      "target": "DB00002",
      "description": "Trastuzumab may increase the cardiotoxic activities of Cetuximab.",
      "name": "Cetuximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00091",
      "source": "DB00072",
      "target": "DB00091",
      "description": "Trastuzumab may increase the neutropenic activities of Cyclosporine.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00004",
      "source": "DB00072",
      "target": "DB00004",
      "description": "Trastuzumab may increase the cardiotoxic activities of Denileukin diftitox.",
      "name": "Denileukin diftitox"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00095",
      "source": "DB00072",
      "target": "DB00095",
      "description": "Trastuzumab may increase the neutropenic activities of Efalizumab.",
      "name": "Efalizumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00005",
      "source": "DB00072",
      "target": "DB00005",
      "description": "Trastuzumab may increase the neutropenic activities of Etanercept.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00056",
      "source": "DB00072",
      "target": "DB00056",
      "description": "Trastuzumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.",
      "name": "Gemtuzumab ozogamicin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00014",
      "source": "DB00072",
      "target": "DB00014",
      "description": "Trastuzumab may increase the cardiotoxic activities of Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00078",
      "source": "DB00072",
      "target": "DB00078",
      "description": "Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00065",
      "source": "DB00072",
      "target": "DB00065",
      "description": "Trastuzumab may increase the neutropenic activities of Infliximab.",
      "name": "Infliximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00060",
      "source": "DB00072",
      "target": "DB00060",
      "description": "Trastuzumab may increase the cardiotoxic activities of Interferon beta-1a.",
      "name": "Interferon beta-1a"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00068",
      "source": "DB00072",
      "target": "DB00068",
      "description": "Trastuzumab may increase the cardiotoxic activities of Interferon beta-1b.",
      "name": "Interferon beta-1b"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00007",
      "source": "DB00072",
      "target": "DB00007",
      "description": "Trastuzumab may increase the cardiotoxic activities of Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00075",
      "source": "DB00072",
      "target": "DB00075",
      "description": "Trastuzumab may increase the neutropenic activities of Muromonab.",
      "name": "Muromonab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00104",
      "source": "DB00072",
      "target": "DB00104",
      "description": "Trastuzumab may increase the cardiotoxic activities of Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00038",
      "source": "DB00072",
      "target": "DB00038",
      "description": "Trastuzumab may increase the cardiotoxic activities of Oprelvekin.",
      "name": "Oprelvekin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00059",
      "source": "DB00072",
      "target": "DB00059",
      "description": "Trastuzumab may increase the cardiotoxic activities of Pegaspargase.",
      "name": "Pegaspargase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00073",
      "source": "DB00072",
      "target": "DB00073",
      "description": "Trastuzumab may increase the cardiotoxic activities of Rituximab.",
      "name": "Rituximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00081",
      "source": "DB00072",
      "target": "DB00081",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00072-DB00081",
      "source": "DB00072",
      "target": "DB00081",
      "description": "Trastuzumab may increase the neutropenic activities of Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00054",
      "source": "DB00078",
      "target": "DB00054",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00102",
      "source": "DB00078",
      "target": "DB00102",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Ibritumomab tiuxetan.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00006",
      "source": "DB00078",
      "target": "DB00006",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00063",
      "source": "DB00078",
      "target": "DB00063",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00001",
      "source": "DB00078",
      "target": "DB00001",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Ibritumomab tiuxetan.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00078-DB00072",
      "source": "DB00078",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00054",
      "source": "DB00081",
      "target": "DB00054",
      "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00102",
      "source": "DB00081",
      "target": "DB00102",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Tositumomab.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00006",
      "source": "DB00081",
      "target": "DB00006",
      "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00063",
      "source": "DB00081",
      "target": "DB00063",
      "description": "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00001",
      "source": "DB00081",
      "target": "DB00001",
      "description": "The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00072",
      "source": "DB00081",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Tositumomab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00081-DB00072",
      "source": "DB00081",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Tositumomab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00083-DB00042",
      "source": "DB00083",
      "target": "DB00042",
      "description": "Botulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.",
      "name": "Botulinum Toxin Type B"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00047",
      "source": "DB00082",
      "target": "DB00047",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Glargine.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00030",
      "source": "DB00082",
      "target": "DB00030",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Human.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00046",
      "source": "DB00082",
      "target": "DB00046",
      "description": "Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00082-DB00104",
      "source": "DB00082",
      "target": "DB00104",
      "description": "The risk or severity of adverse effects can be increased when Octreotide is combined with Pegvisomant.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00054",
      "source": "DB00086",
      "target": "DB00054",
      "description": "Streptokinase may increase the anticoagulant activities of Abciximab.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00041",
      "source": "DB00086",
      "target": "DB00041",
      "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.",
      "name": "Aldesleukin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00102",
      "source": "DB00086",
      "target": "DB00102",
      "description": "Streptokinase may increase the anticoagulant activities of Becaplermin.",
      "name": "Becaplermin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00006",
      "source": "DB00086",
      "target": "DB00006",
      "description": "Streptokinase may increase the anticoagulant activities of Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00063",
      "source": "DB00086",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Streptokinase.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00086-DB00001",
      "source": "DB00086",
      "target": "DB00001",
      "description": "Streptokinase may increase the anticoagulant activities of Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00087-DB00072",
      "source": "DB00087",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Alemtuzumab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00092-DB00072",
      "source": "DB00092",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Alefacept.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00095-DB00072",
      "source": "DB00095",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Efalizumab.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00051",
      "source": "DB00091",
      "target": "DB00051",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.",
      "name": "Adalimumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00058",
      "source": "DB00091",
      "target": "DB00058",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.",
      "name": "Alpha-1-proteinase inhibitor"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00006",
      "source": "DB00091",
      "target": "DB00006",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00005",
      "source": "DB00091",
      "target": "DB00005",
      "description": "Etanercept may increase the nephrotoxic activities of Cyclosporine.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00027",
      "source": "DB00091",
      "target": "DB00027",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Gramicidin D.",
      "name": "Gramicidin D"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00001",
      "source": "DB00091",
      "target": "DB00001",
      "description": "The serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00104",
      "source": "DB00091",
      "target": "DB00104",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.",
      "name": "Octreotide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00091-DB00072",
      "source": "DB00091",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Cyclosporine.",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00098-DB00072",
      "source": "DB00098",
      "target": "DB00072",
      "description": "Trastuzumab may increase the neutropenic activities of Anti-thymocyte Globulin (Rabbit).",
      "name": "Trastuzumab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00054",
      "source": "DB00102",
      "target": "DB00054",
      "description": "Abciximab may increase the anticoagulant activities of Becaplermin.",
      "name": "Abciximab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00009",
      "source": "DB00102",
      "target": "DB00009",
      "description": "Alteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Alteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00029",
      "source": "DB00102",
      "target": "DB00029",
      "description": "Anistreplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Anistreplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00006",
      "source": "DB00102",
      "target": "DB00006",
      "description": "Bivalirudin may increase the anticoagulant activities of Becaplermin.",
      "name": "Bivalirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00055",
      "source": "DB00102",
      "target": "DB00055",
      "description": "Drotrecogin alfa may increase the anticoagulant activities of Becaplermin.",
      "name": "Drotrecogin alfa"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00063",
      "source": "DB00102",
      "target": "DB00063",
      "description": "Eptifibatide may increase the anticoagulant activities of Becaplermin.",
      "name": "Eptifibatide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00005",
      "source": "DB00102",
      "target": "DB00005",
      "description": "Etanercept may increase the anticoagulant activities of Becaplermin.",
      "name": "Etanercept"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00078",
      "source": "DB00102",
      "target": "DB00078",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Ibritumomab tiuxetan.",
      "name": "Ibritumomab tiuxetan"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00001",
      "source": "DB00102",
      "target": "DB00001",
      "description": "Lepirudin may increase the anticoagulant activities of Becaplermin.",
      "name": "Lepirudin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00015",
      "source": "DB00102",
      "target": "DB00015",
      "description": "Reteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Reteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00086",
      "source": "DB00102",
      "target": "DB00086",
      "description": "Streptokinase may increase the anticoagulant activities of Becaplermin.",
      "name": "Streptokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00031",
      "source": "DB00102",
      "target": "DB00031",
      "description": "Tenecteplase may increase the anticoagulant activities of Becaplermin.",
      "name": "Tenecteplase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00081",
      "source": "DB00102",
      "target": "DB00081",
      "description": "The risk or severity of adverse effects can be increased when Becaplermin is combined with Tositumomab.",
      "name": "Tositumomab"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00102-DB00013",
      "source": "DB00102",
      "target": "DB00013",
      "description": "Urokinase may increase the anticoagulant activities of Becaplermin.",
      "name": "Urokinase"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00091",
      "source": "DB00104",
      "target": "DB00091",
      "description": "The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.",
      "name": "Cyclosporine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00014",
      "source": "DB00104",
      "target": "DB00014",
      "description": "Octreotide may increase the QTc-prolonging activities of Goserelin.",
      "name": "Goserelin"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00047",
      "source": "DB00104",
      "target": "DB00047",
      "description": "Insulin Glargine may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Glargine"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00030",
      "source": "DB00104",
      "target": "DB00030",
      "description": "Insulin Human may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Human"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00046",
      "source": "DB00104",
      "target": "DB00046",
      "description": "Insulin Lispro may increase the hypoglycemic activities of Octreotide.",
      "name": "Insulin Lispro"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00071",
      "source": "DB00104",
      "target": "DB00071",
      "description": "The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Octreotide.",
      "name": "Insulin Pork"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00007",
      "source": "DB00104",
      "target": "DB00007",
      "description": "Octreotide may increase the QTc-prolonging activities of Leuprolide.",
      "name": "Leuprolide"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00082",
      "source": "DB00104",
      "target": "DB00082",
      "description": "The risk or severity of adverse effects can be increased when Octreotide is combined with Pegvisomant.",
      "name": "Pegvisomant"
    }
  },
  {
    "group": "edges",
    "data": {
      "id": "DB00104-DB00072",
      "source": "DB00104",
      "target": "DB00072",
      "description": "Trastuzumab may increase the cardiotoxic activities of Octreotide.",
      "name": "Trastuzumab"
    }
  }
]